Premium
A synthetic thymic hormone, THF‐γ2, repairs immunodeficiency of mice cured of plasmacytoma by melphalan
Author(s) -
Ophir R.,
Pecht M.,
Rashid G.,
Halperin D.,
Lourie S.,
Burstein Y.,
BenEfraim S.,
Trainin S.
Publication year - 1990
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910450633
Subject(s) - plasmacytoma , melphalan , in vivo , spleen , in vitro , cd8 , antibody , immunology , medicine , cancer research , chemotherapy , biology , immune system , multiple myeloma , biochemistry , microbiology and biotechnology
BALB/c mice cured of large MOPC‐315 plasmacytomas by melphalan remain deficient in their spleen T‐cell functions. This was manifested by impairment of the allogeneic and the antibody responses in vitro to SRBC and in decreased numbers of T‐cells including their subsets CD4 and CD8. IL‐2 production and specific cytotoxicity against MOPC‐315 tumor cells were, on the other hand, maintained. Treatment of these cured mice by in‐vivo administration of THF‐γ2, an octapeptide from calf thymus, repaired these deficits. This was evidenced by in vitro tests with spleen cells which manifested an increased allogeneic response and elevated generation of primary antibody response, restoration of T‐cell subpopulations to normal and an enhanced IL‐2 production above normal levels. The potential use of THF‐γ2 as supportive therapy in cancer treatment is suggested.